Outlook Therapeutics Statistics Share Statistics Outlook Therapeutics has 44.42M
shares outstanding. The number of shares has increased by null%
in one year.
Shares Outstanding 44.42M Shares Change (YoY) n/a Shares Change (QoQ) n/a Owned by Institutions (%) 22.95% Shares Floating n/a Failed to Deliver (FTD) Shares 13,889 FTD / Avg. Volume 0.44%
Short Selling Information The latest short interest is 2.92M, so 6.56% of the outstanding
shares have been sold short.
Short Interest 2.92M Short % of Shares Out 6.56% Short % of Float 7.97% Short Ratio (days to cover) 2.07
Valuation Ratios The PE ratio is -1.31 and the forward
PE ratio is -0.9.
Outlook Therapeutics's PEG ratio is
0.09.
PE Ratio -1.31 Forward PE -0.9 PS Ratio 0 Forward PS 2.2 PB Ratio -1.36 P/FCF Ratio -1.44 PEG Ratio 0.09
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Outlook Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.64,
with a Debt / Equity ratio of -0.41.
Current Ratio 0.64 Quick Ratio 0.64 Debt / Equity -0.41 Debt / EBITDA -0.41 Debt / FCF -0.43 Interest Coverage -22.71
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-3.28M Employee Count 23 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 2.8K Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -83.2% in the
last 52 weeks. The beta is 0.49, so Outlook Therapeutics's
price volatility has been higher than the market average.
Beta 0.49 52-Week Price Change -83.2% 50-Day Moving Average 1.92 200-Day Moving Average 1.8 Relative Strength Index (RSI) 37.03 Average Volume (20 Days) 3,157,098
Income Statement
Revenue n/a Gross Profit -113.86K Operating Income -71.7M Net Income -75.37M EBITDA -72.09M EBIT -72.21M Earnings Per Share (EPS) -4.06
Full Income Statement Balance Sheet The company has 14.93M in cash and 29.74M in
debt, giving a net cash position of -14.81M.
Cash & Cash Equivalents 14.93M Total Debt 29.74M Net Cash -14.81M Retained Earnings -543.28M Total Assets 22.39M Working Capital -10.39M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -68.79M
and capital expenditures 0, giving a free cash flow of -68.79M.
Operating Cash Flow -68.79M Capital Expenditures n/a Free Cash Flow -68.79M FCF Per Share -3.71
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields OTLK does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for OTLK is $6,
which is 450.5% higher than the current price. The consensus rating is "Hold".
Price Target $6 Price Target Difference 450.5% Analyst Consensus Hold Analyst Count 5
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Mar 14, 2024. It was a
backward
split with a ratio of 1:20.
Last Split Date Mar 14, 2024 Split Type backward Split Ratio 1:20
Scores Altman Z-Score -43.52 Piotroski F-Score 2
